Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks
| Autor: | Ingo Sabatschus, Jiří Létal, E. Dietlind Koch, Sofia Kapanadze, Marie-Henriette Eerdekens, Georg Kralidis, Sam H Ahmedzai |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Indoles Analgesic 03 medical and health sciences 0302 clinical medicine medicine Humans Spiro Compounds 030212 general & internal medicine General Nursing Aged Pain Measurement Polypharmacy Analgesics business.industry Cebranopadol Cancer Pain Middle Aged Effective dose (pharmacology) Clinical trial Anesthesiology and Pain Medicine Treatment Outcome Tolerability 030220 oncology & carcinogenesis Anesthesia Morphine Female Neurology (clinical) Cancer pain business medicine.drug |
| Zdroj: | Journal of pain and symptom management. 58(3) |
| ISSN: | 1873-6513 |
| Popis: | Context Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. For cancer patients, frequently experiencing multimorbidities and often exposed to polypharmacy, cebranopadol is easy to handle given its once-daily dosing, the small tablet size that enables swallowing, and the option to flexibly titrate to an effective dose. Objectives We assessed the safety and tolerability of prolonged treatment with oral cebranopadol for up to 26 weeks in patients suffering from chronic moderate-to-severe cancer-related pain. Methods This was a non-randomized, multi-site, open-label, single-arm clinical trial with patients who had completed a double-blind trial comparing morphine prolonged release with cebranopadol. In this extension trial, patients were treated with oral cebranopadol for up to 26 weeks. Results Cebranopadol was safe and well tolerated in patients with chronic moderate-to-severe pain related to cancer in the dose range tested (200–1000 μg once daily). The median and mean pain levels remained in the range of mild pain during the treatment period. Conclusion Our data suggest that cebranopadol was safe and well tolerated when administered for up to 26 weeks in patients with chronic cancer-related pain who were previously treated with cebranopadol or morphine prolonged release. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect